Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received approval from the Ministry of Food and Drug Safety (MFDS) of South Korea for its Phase 3 Clinical Trial Application (IND) of CT-P13 SC (Remsima Subcutaneous) in pediatric patients with moderately to severely active Crohn’s disease. 📊 Key Disclosure Content & Financial Highlights 📝…

Read More “[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Application for CT-P13 SC (Remsima Subcutaneous) in Pediatric Crohn’s Disease in Korea / 2025-02-24” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen disclosed that the 100% payment for its previously resolved third-party allotment paid-in capital increase (redeemable convertible preferred stocks) worth KRW 155.00B has been successfully completed. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Delivery of New Shares and Mandatory…

Read More “[Disclosure] ALTEOGEN (196170) – Result of Securities Issuance (Voluntary Disclosure) / 2025-02-19” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion decided to acquire 554,632 treasury common shares worth approximately KRW 100.0B through on-market purchases to stabilize its stock price and enhance shareholder value. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Execution of On-Market Purchases and Completion of Acquisition…

Read More “[Disclosure] Celltrion (068270) – Treasury Share Acquisition Decision / 2025-02-19” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received final marketing authorization from the European Commission (EC) for Stoboclo and Osenvelt (CT-P41), biosimilars to Prolia and Xgeva, covering all reference indications across 30 European countries. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of EC Marketing…

Read More “[Disclosure] Celltrion (068270) – Approval of European Commission Marketing Authorization for Stoboclo & Osenvelt (CT-P41, Prolia & Xgeva Biosimilars) / 2025-02-18” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received simultaneous approval for both Part 1 (clinical design) and Part 2 (trial sites and execution) of its Phase 3 Clinical Trial Application (CTA) for CT-P55, a Cosentyx biosimilar candidate, from the European Medicines Agency (EMA). 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s…

Read More “[Disclosure] Celltrion (068270) – Approval of Part 1 & Part 2 Clinical Trial Application for Phase 3 Trial of CT-P55 (Cosentyx Biosimilar) in Europe / 2025-02-18” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen is participating in an overseas IR conference in Hong Kong and Singapore from February 17 to February 20, 2025, to present its R&D pipelines, progress on licensed agreements, and long-term growth strategies to foreign institutional investors. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s…

Read More “[Disclosure] ALTEOGEN (196170) – Investor Relations (IR) Holding / 2025-02-14” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received final marketing authorization from the European Commission (EC) for Eydenzelt (CT-P42), a biosimilar to Eylea, covering major ophthalmic indications across 30 European countries. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of EC Marketing Authorization Listing in…

Read More “[Disclosure] Celltrion (068270) – Approval of European Commission Marketing Authorization for Eydenzelt (CT-P42, Eylea Biosimilar) / 2025-02-14” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that it expects to disclose its tentative financial results for FY2024 (2024-01-01 to 2024-12-31) on February 25, 2025. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of FY2024 Preliminary Financial Results Disclosure This disclosure serves as official…

Read More “[Disclosure] Celltrion (068270) – Advance Notice of Financial Results Disclosure / 2025-02-14” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received marketing authorization from the Ministry of Food and Drug Safety (MFDS) of South Korea for Avtozma Subcutaneous Injection (CT-P47), a biosimilar referencing Actemra, for the treatment of rheumatoid arthritis. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification…

Read More “[Disclosure] Celltrion (068270) – Approval of Korean MFDS Marketing Authorization for Avtozma Subcutaneous Injection (CT-P47, Actemra Biosimilar) / 2025-02-13” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has announced a board resolution to convene its 14th Annual General Meeting (AGM) of Shareholders on March 14, 2025, at 09:00 KST at Songdo Convensia. Proposed agenda items include the approval of FY2024 financial statements, amendments to the articles of incorporation, appointments of directors…

Read More “[Disclosure] Samsung Biologics (207940) – Decision to Convene General Meeting of Shareholders / 2025-02-12” »